Fortress Biotech (FBIO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of seven directors is on the agenda, with all nominees recommended by the board.
Ratification of KPMG LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.
Proxy may vote on other business that arises during the meeting or any adjournment.
Board of directors and corporate governance
Board nominees include Lindsay A. Rosenwald, Michael S. Weiss, Jimmie Harvey Jr., Malcolm Hoenlein, Dov Klein, J. Jay Lobell, and Kevin L. Lorenz.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fortress Biotech
- Q2 2026 revenue up 14% to $18.7M, with a $158.9M PRV gain and strong cash reserves.FBIO
Q2 2026 - Triplex delivers robust efficacy and safety in CMV prevention for transplants, targeting $1B+ peak sales.FBIOCorporate presentation
- Proprietary bioreactor boosts MSC potency, enabling lower dosing and major cost savings.FBIOCorporate presentation
- Directors and auditors for 2026 were approved by shareholders, concluding the meeting.FBIOAGM 2026
- Three FDA approvals, strong revenue, and a robust late-stage pipeline drive near-term growth.FBIOCorporate presentation
- Scalable, royalty-driven model and recent monetizations fuel growth and strengthen financial position.FBIOA.G.P.'s Annual Virtual Healthcare Conference
- Q1 2026 net income jumped to $108.4M on a $205M PRV sale and 21–22% revenue growth.FBIOQ1 2026
- Shareholders will vote virtually on director elections, auditor ratification, and equity-based executive pay.FBIOProxy filing
- Two FDA approvals and a major acquisition highlight Fortress Biotech's transformative 2024.FBIOQ4 2024